2025-12-25 - Analysis Report
Okay, here's a comprehensive analysis of Recursion Pharmaceuticals Inc. (RXRX), based on the provided data.

**1) Return Rate Comparison**

*   **Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to discover, develop, and commercialize novel therapeutics.
*   **RXRX Cumulative Return:** -31.02%
*   **VOO (S&P 500) Cumulative Return:** 42.87%
*   **Divergence:** -73.9 (Relative Divergence: 0.3)

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period covered.  The negative divergence indicates that the underperformance is substantial. The relative divergence of 0.3 suggests the current divergence is near the minimum within the observed historical range of divergence between RXRX and VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 22.0% | 81.0% | 26.0% | -0.2 | 5.3 |
| 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1 | 3.6 |
| 2023-2025  | 11.0% | 80.0% | -54.0% | 0.1 | 2.3 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows a declining trend, suggesting slowing growth over the periods observed.
*   **MDD:**  The Maximum Drawdown (MDD) is consistently high (around 80%), indicating substantial risk and volatility.
*   **Alpha:** The alpha decreased significantly year by year, it means the investment's performance relative to the market has worsened. Starting strong from 26% between 2021-2023, it plummeted to -54% for 2023-2025.
*   **Beta:** The beta is fluctuating around 0. This suggest that the stock's price is not particularly reactive to market movements.
*   **Cap:**  The market capitalization decreases year by year, which may explain a loss of confidence.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 4.26
*   **Last-Market:** Price: 4.4, Previous Close: 4.36, Change: 0.92%
*   **5-day SMA:** 4.356
*   **20-day SMA:** 4.4978
*   **60-day SMA:** 5.0218

**Analysis:** The stock price is currently below all three moving averages (5-day, 20-day, and 60-day SMA). This *could* be interpreted as a short-term downtrend. However, the last market data shows a positive change, suggesting a potential short-term rebound.

**3) Indicators Analysis**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment)
*   **RSI (Relative Strength Index):** 46.19
*   **PPO (Percentage Price Oscillator):** 0.0634
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) Relative Divergence Change:** -0.5 (short-term decline)
*   **Expected Return (%):** -552.1%

**Analysis:**

*   **MRI:** The MRI suggests a medium level of investment risk.
*   **RSI:** An RSI of 46.19 is considered neutral. It doesn't indicate that the stock is overbought or oversold.
*   **PPO:** A PPO of 0.0634 means that the 26-day EMA is slightly above the 12-day EMA. This could signal an upward trend but needs further confirmation.
*   **Hybrid Signal:** The hybrid signal indicates a strong buy recommendation with a Very Safe risk rating. This seems contradictory to the low RSI and the expected return.
*   **Divergence Change:** The negative divergence change over the last 20 days confirms a recent downward trend relative to the S&P 500.
*   **Expected Return:** The very negative expected return is concerning.

**4) Recent News & Significant Events**

*   **Positive News Catalysts:**
    *   Analysts refocusing on REC-4881 data
    *   ARK Investment Management buying RXRX stock
    *   Cathie Wood doubling down on Recursion Pharma
    *   J.P. Morgan upgrades RXRX
    *   Trial data gains
*   **Other News:**
    *   2026 CEO transition
    *   Analyst Upgrade and Clinical Data

**Analysis:** Recent news is a mixed bag. The analyst upgrades (J.P. Morgan), positive data focus, and ARK's continued investment are positive signals. However, the CEO transition could introduce uncertainty. The overall sentiment leans slightly positive based on these headlines.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (2.50 ~ Hold)
*   **Opinions:** 7 analysts
*   **Target Price:** Avg: $7.00 / High: $11.00 / Low: $3.00

**Analysis:** The analyst consensus is a "Buy," leaning towards "Hold."  The average target price of $7.00 suggests significant upside potential from the current price of around $4.26. However, the wide range between the high and low target prices indicates a considerable level of uncertainty among analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | -0.36 | 0.01 B$    |
| 2025-08-05 | -0.41 | 0.02 B$    |
| 2025-05-05 | -0.50 | 0.01 B$    |
| 2024-11-06 | -0.34 | 0.03 B$    |
| 2025-11-05 | -0.34 | 0.03 B$    |

**Analysis:**

*   **EPS:** The company consistently reports negative Earnings Per Share (EPS), indicating a lack of profitability. While the recent EPS improved to -0.36, it is still negative.
*   **Revenue:** Revenue is relatively low and fluctuating. The trend suggests stagnation, which is a point of concern.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $0.00B     | -194.74%      |
| 2025-06-30   | $0.02B     | -5.54%        |
| 2025-03-31   | $0.01B     | -47.31%      |
| 2024-12-31   | $0.00B     | -183.62%      |
| 2024-09-30   | $0.03B     | 53.69%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $1.05B    | -15.50%  |
| 2025-06-30   | $0.92B    | -18.70%  |
| 2025-03-31   | $0.93B    | -21.68%  |
| 2024-12-31   | $1.03B    | -17.29%  |
| 2024-09-30   | $0.52B    | -18.27%  |

**Analysis:**

*   **Revenue:** Revenue generation is inconsistent and generally low.
*   **Profit Margin:** The profit margins are overwhelmingly negative, showing a significant loss-making trend. The one positive profit margin in Q3 2024 is an outlier.
*   **Equity:** While equity has fluctuated, it's generally maintained at a reasonable level.
*   **ROE:** Return on Equity (ROE) is consistently negative, indicating an inability to generate profits from shareholders' investments.

**7) Comprehensive Analysis (Summary)**

RXRX presents a mixed picture.

*   **Negatives:**
    *   Significant underperformance compared to the S&P 500.
    *   Consistently negative EPS, revenue, and ROE
    *   High volatility (MDD)
    *   Large negative expected return.
*   **Positives:**
    *   Recent positive news catalysts (analyst upgrades, ARK investment).
    *   Analyst consensus is leaning towards a "Buy" rating, with significant upside potential (although uncertainty is high).
    *   Relatively stable Equity.
    *   The Hybrid Signal indicates a strong buy recommendation with a Very Safe risk rating.

**Conclusion:**

Investing in RXRX appears high-risk at the moment. While analyst upgrades and institutional investment are positive signs, the company's financial performance (negative earnings, low revenue, high volatility) raises significant concerns. Potential investors should carefully weigh the risk factors and conduct further due diligence before making a decision. The "Buy" recommendation from analysts should be viewed with caution, given the current financial metrics and the wide range in target prices. The high negative Expected Return (%) is a major red flag.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.